SEC Filing Summary for CRISPR Therapeutics AG

Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics AG, reported a series of transactions involving the company's Common Shares and Restricted Stock Units (RSUs). On March 14, 2026, Kulkarni acquired 20,625 Common Shares via the settlement of RSUs, which were granted on March 14, 2025, with vesting scheduled over four years. The RSUs represent a contingent right to one Common Share each. This acquisition was part of a lock-up agreement with the underwriters of the company's convertible senior notes. Additionally, on March 16, 2026, Kulkarni disposed of 10,349 Common Shares at a price of $48.26 per share. This sale was mandated by the company's RSU Settlement Policy to cover tax withholding obligations upon the vesting of RSUs, and it does not represent a discretionary trade. Following these transactions, Kulkarni's post-transaction share ownership stands at 245,834 Common Shares.